Observational studyHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2020
Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.
Observational study in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.World journal of gastroenterology · 2021Trial
- Article
- Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.European journal of heart failure · 2025Article
- Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk.Alimentary pharmacology & therapeutics · 2025Article
- TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.Hepatology forum · 2023Article
- Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.Journal of cardiovascular development and disease · 2022Review
- Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study.PloS one · 2022Article
- Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe study aimed to investigate, in patients with primary non-alcoholic fatty liver disease (NAFLD), the presence of possible relationships between the degree of steatosis or fibrosis and the individual cardiovascular risk and possibly whether a difference between those various methods exists.
methodsThirty-four adult patients with primary NAFLD were included in this study. Clinical evaluation included an ultrasonographic examination for the determination of the severity of steatosis. Two different clinical indirect indexes of the severity of hepatic fibrosis were used: the FIB-4 score and the NAFLD fibrosis score. Then, the individual cardiovascular 10-years risk according to 5 different scores: "Progetto Cuore" of the Italian Institute of Health, Framingham score 2004-ATP III, Framingham risk score 2008, ACC/AHA ASCVD risk score 2013, ACC/AHA ASCV risk score new model score 2 were estimated.
resultsThe severity of steatosis evaluated by ultrasonography was significantly correlated only with ACC/AHA ASCVD RISK 2013, ACC/AHA ASCVD New Model 2 2018 and Framingham 2008 risk scores. The severity of fibrosis evaluated by the FIB-4 score or with NAFLD fibrosis score was significantly correlated only with cardiovascular risk evaluated with ACC/AHA ASCVD 2013, ACC/AHA ASCVD New Model 2 2018 and Framingham risk score 2008.
conclusionsSome of the methods for the estimation of cardiovascular risk (ACC/AHA ASCVD 2013, new model 2 2018, and, also Framingham score 2008) have a clear advantage over Framingham score 2004 and "Progetto Cuore" of the Italian Institute of Health in terms of correlation with the severity of NAFLD. They are, therefore, more clinically useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.